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Although percutaneous transluminal angioplasty is widely
used to treat patients with vascular diseases, restenosis
remains a major limitation, affecting about one-third of
patients (1–4). Despite the benefits of stent implantation
and brachytherapy, as well as the new excitement over
drug-eluting stents, restenosis will remain a challenging
problem (1–3). These advances of interventional technolo-
gies will encourage us to push the threshold of intervention
further by approaching more difficult lesions in smaller
vessels, and what we now consider to be clinically insignif-
icant restenosis will become important.
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Until recently, the translation of basic vascular biology
studies into clinically effective therapies for restenosis has
largely been a failure (3). Many therapies inhibited intimal
proliferation in animals, but few worked in humans. When-
ever basic laboratory science seems to stumble like this,
there are many possibilities, such as differences between
species and deficiencies in our experimental models. An-
other major reason for a mismatch between the laboratory
and the clinic is that central assumptions of the pathophys-
iology are incorrect, so that researchers are looking for the
wrong things in the laboratory, or perhaps even testing the
wrong hypotheses. When this occurs, it sometimes takes a
revolution in thinking to set things straight.
We are in the midst of such a revolution in all fields of
tissue repair, and vascular injury is no exception. The
apparent ability of some adult progenitor cells, either
circulating or endogenous within a tissue, to change phe-
notype dramatically is leading us to reconsider theories of
tissue repair. Although this revolution is just beginning, and
major controversies abound, it is already clear that our
textbook figures of intimal cells arising from migration out
of the existing media will require revision. In fact, major
questions are arising about what defines a given type of cell,
and many of our usual histopathologic classifications of cells
in the tradition of Virchow may also need revision. Careful
use of multiple specific cell markers is already suggesting
that some cells are not what we think they are (5).
Restenotic lesions following arterial intervention are dif-
ferent from typical atherosclerotic plaques. Whereas athero-
sclerotic plaques accumulate lipid, calcification, and fibrosis,
restenotic lesions are typically a more homogeneous mix of
cells and extracellular matrix. Early studies suggested that
injury that denudes the endothelial layer induces platelet
and fibrin deposition immediately after injury, subsequently
stimulating vascular smooth-muscle cell migration, prolif-
eration, and extracellular matrix synthesis. Thus, early
attempts to limit restenosis logically focused on antithrom-
botic mechanisms or strategies to slow smooth-muscle cell
proliferation; most failed to inhibit restenosis in humans
(1,3,6).
On the basis of the biology of wound healing, a role of
inflammation in the development of restenosis also emerged
(1,4). Thrombus formation or the injury itself initiates
recruitment of leukocytes to the injury (1,7). The interaction
between platelets and leukocytes may amplify the inflam-
matory response, as the binding of leukocytes to platelets
induces leukocyte activation steps such as integrin activation
and chemokine synthesis. The increase in the expression of
adhesion molecules on neutrophils and monocytes and
circulating levels of inflammatory markers correlate with the
incidence of restenosis in humans, and inhibition of inflam-
mation by inhibiting chemokine receptors or adhesion
molecules attenuates neointima formation in animal models
(1,8–10). This supports the important role of inflammatory
cells in neointima formation.
In these and other models of restenosis, endogenous
smooth muscle cells from the intima, media, and adventitia
are the source of proliferating cells and extracellular matrix
(1,4,8,11). This traditional scheme has now been challenged
by studies showing that circulating blood contains vascular
smooth muscle cell progenitors that contribute to the
formation of vascular lesions. Several reports showed that in
transplant atherosclerosis, donor intimal smooth muscle
cells are derived from host bone marrow cells (12–14).
Subsequently, it was demonstrated that bone marrow-
derived cells contribute to neointima formation in vascular
injury (15). Furthermore, bone marrow cells or blood
mononuclear cells can differentiate into cells with vascular
smooth muscle cell markers (15,16).
Dendritic cells, so named because of their long membrane
extensions, are specialized innate immunity cells. These
professional antigen-presenting cells constitutively express
high levels of both class I and class II MHC molecules and
members of the co-stimulatory B7 family. After capturing
antigen in tissues by phagocytosis or endocytosis, dendritic
cells migrate into the blood or lymph and circulate to
various lymphoid organs, where they present antigens to T
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the †Cardiovascular Division, Department of Medicine, Brigham and
Women’s Hospital, Harvard Medical School, Boston, Massachusetts, and the
‡Division of Biological Engineering, Massachusetts Institute of Technology, Cam-
bridge, Massachusetts.
Journal of the American College of Cardiology Vol. 42, No. 5, 2003
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Inc. doi:10.1016/S0735-1097(03)00840-4
lymphocytes. Dendritic cells are not a single cell type, but a
system of cells that arise from distinct lineages with different
functions (17–19). Although the principal function of den-
dritic cells is to induce T-cell immunity by presenting
antigens to T lymphocytes, dendritic cells are also essential
to maintain self-tolerance by inducing apoptotic cell death
of potentially harmful self-reactive T-cells (17,20).
In this issue of the Journal, Bauriedel et al. (21) identify
dendritic cells at the site of vascular injury by immunostain-
ing with OX-62 and S100 antibodies and with electron
microscopy. These cells first appear as adherent cells along
the internal elastic lamina four days after injury, and at day
7, they constitute approximately half of the cellular content
of neointima. Thereafter, numbers of cells with dendritic
antigens decrease, whereas OX-62 immunoreactive cells are
still evident along the luminal surface of advanced neoin-
tima at day 28. The study also demonstrates that these
dendritic cells express Bcl-2 and HSP47 during all stages of
neointima development. Although this study did not define
a functional role for dendritic cells in the development of
neointima, these new data raise interesting questions. Rel-
atively little is known about subpopulations of rat dendritic
cells compared with mouse or human dendritic cells, but rat
dendritic cells can also be classified into subsets that elicit
different functions in immunologic reactions (17,19,22,23).
In mice and humans, using expression of surface markers
such as CD4, CD8, and CD11, dendritic cells can be
grouped as myeloid dendritic cells or DC1, and lymphoid
dendritic cells or DC2, which exhibit different functions. In
general, myeloid dendritic cells can produce large amounts
of interleukin 12 upon exposure to pathogens and drive
T-cells to differentiate into Th1 cells; lymphoid dendritic
cells produce large amounts of interferons upon exposure to
virus and drive differentiation of Th2 cells (17,20). Although
OX-62 antigen (-integrin) may be preferentially expressed
on lymphoid dendritic cells (19,22), identification of dendritic
cell subsets present in neointima would provide important
insight in the role of dendritic cells in neointima formation.
In addition, this study demonstrated that not only the
proportion of dendritic cells in neointima, but also the
absolute number of dendritic cells decreases during the
development of neointima (21), which suggests that den-
dritic cells migrate out from the lesion. If this is the case,
these cells might migrate back to lymphoid tissues, where
they modulate T-cell functions. It may also be conceivable
that these dendritic cells transdifferentiate into vascular
smooth muscle-like cells and form cells of the neointima.
Recent studies show that mononuclear cells in human blood
can give rise to cells positive for vascular smooth muscle cell
markers (16), and most dendritic cells are thought to
originate from hematopoietic stem cells and to share some
initial steps of their differentiation with monocytes (17,24).
Our reassessment of where cells of the injured vessel are
coming from, who they are, and what they are doing is just
beginning. Examination of the involvement of dendritic
cells in vascular lesions in other animal models as well as
humans and identification of subsets of dendritic cells
present in vascular lesions are important issues. Identifica-
tion of the origin and the fate of dendritic cells in vascular
lesions will provide important insights in the biology of
vascular lesions and perhaps clues to new therapeutic op-
tions for restenosis.
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